Akebia Therapeutics Inc
F:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
F:AX9
|
US |
|
B
|
British American Tobacco PLC
DUS:BMT
|
UK |
|
Valneva SE
F:AYJ0
|
FR |
|
P
|
Pernod Ricard SA
XMUN:PER
|
FR |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 7.66 EUR with a low forecast of 5.17 EUR and a high forecast of 10.76 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
7.66
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 7.66 EUR with a low forecast of 5.17 EUR and a high forecast of 10.76 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
12%
The compound annual growth rate for Revenue over the next 8 years is 12%.
What is the Operating Income forecast for Akebia Therapeutics Inc?
Projected CAGR
39%
The compound annual growth rate for Operating Income over the next 8 years is 39%.
